2025
Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
Huang S, Westvold S, Soulos P, Fan J, Winer E, Zhan H, Lustberg M, Lewin J, Robinson T, Dinan M. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open 2025, 8: e255322. PMID: 40232715, DOI: 10.1001/jamanetworkopen.2025.5322.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityBreast cancer mortalityBreast cancer diagnosisCancer-specific mortalityCancer mortalityCancer diagnosisScreening mammographyHazard of breast cancer-specific deathFee-for-service Medicare Parts AAssociated with reduced breast cancer mortalityLower breast cancer mortalityHazard of breast cancer-specific mortalityBreast cancerImprove breast cancer outcomesScreen-detected breast cancerCohort studyBreast cancer-specific deathStudy of older womenBreast cancer outcomesFee-for-serviceDetection of breast cancerMedicare Part ALater-stage diseaseCox proportional hazards modelsAssociated with early stagesMachine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial
Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm D, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T. Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. Npj Breast Cancer 2025, 11: 23. PMID: 40055382, DOI: 10.1038/s41523-025-00730-1.Peer-Reviewed Original ResearchPathological complete responseAssociated with pathologic complete responseBreast cancerTriple-negativeCD8+ T cell expressionImmune infiltrate characterizationPretreatment tumor biopsiesTP53-mutated tumorsTumor immune microenvironmentTumor microenvironment componentsT cell expressionImmune cell subsetsTumors of patientsTumor-host interactionsBreast cancer trialsNeoadjuvant trialsComplete responseTN tumorsCD4+Tumor biopsiesCell subsetsPrognostic correlationPrognostic implicationsImmune infiltrationMultiplex immunofluorescenceDeterminants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Callari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall’Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies. Nature Communications 2025, 16: 2195. PMID: 40038334, PMCID: PMC11880565, DOI: 10.1038/s41467-025-57293-9.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesBreast cancerEndocrine therapyImmune infiltrationPrediction of pCRAnti-HER2 therapyLuminal A phenotypeHigher immune infiltrationFemale breast cancerHER2 blockadeDeterminants of responseTumor responseInfiltrating lymphocytesCDK4/6 inhibitionAnti-HER2HER2 targetingClinical endpointsER signalingKi67Response groupCancerTherapyTherapeutic targetMolecular changesTumor110 Characterization of Frequency and Spectrum of PIK3CA Somatic Mutations in Advanced Breast Cancer
Amraei R, Kahn A, Walther Z, Finberg K, Gibson J, Kahila M. 110 Characterization of Frequency and Spectrum of PIK3CA Somatic Mutations in Advanced Breast Cancer. Laboratory Investigation 2025, 105: 102334. DOI: 10.1016/j.labinv.2024.102334.Peer-Reviewed Original ResearchA composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, Solnes L, Abramson V, Carey L, Rimawi M, Specht J, Storniolo A, Vaklavas C, Krop I, Winer E, Denbow R, Valero V, Wolff A, Wahl R, Huang C, Stearns V, Thompson E, Connolly R. A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). The Breast 2025, 81: 104432. PMID: 40049115, PMCID: PMC11928837, DOI: 10.1016/j.breast.2025.104432.Peer-Reviewed Original ResearchTissue-based biomarkersBreast cancerHER2-positive breast cancerHER2 3+Negative predictive valueEarly metabolic changesNeoadjuvant pertuzumabScore cut-offNeoadjuvant therapyIntrinsic subtypesSULmaxC1D15PET/CTDays post-initiationHER2 proteinYouden indexComposite biomarkerDe-intensificationHER2Post-initiationPredictive valueBiomarker performanceC-statisticImaging biomarkersMetabolic changes116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer
Babb P, Theriot J, Liang Y, Cartagena L, Buza N, Krishnamurti U, Zhan H. 116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer. Laboratory Investigation 2025, 105: 102340. DOI: 10.1016/j.labinv.2024.102340.Peer-Reviewed Original ResearchMetastatic breast cancerBreast cancerOncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial
Boughey J, Yu H, Switalla K, Velle L, Lopes A, Wallace A, Lancaster R, Reyna C, Tuttle T, Jaskowiak N, Tchou J, Rao R, Lee M, Naik A, Golshan M, Arciero C, Sauder C, Matsen C, Yau C, Esserman L, Mukhtar R. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2025, 1-14. PMID: 39946078, DOI: 10.1245/s10434-025-16973-y.Peer-Reviewed Original ResearchEvent-free survivalDe-escalation of axillary surgeryLocoregional recurrenceNeoadjuvant chemotherapyALND groupAxillary surgeryOncological outcomesI-SPY2Breast cancerDe-escalationRate of axillary recurrenceMedian follow-up timeShort-term follow-upAxillary surgery typeOmission of ALNDResidual nodal diseaseReduce patient morbidityYpN+ diseaseAdjuvant radiationAxillary recurrenceNodal diseaseYpN+ patientsSurgery typePatient morbidityTrial patientsA pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
Mukhtar R, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy A, Laé M, Reyal F, Sonke G, Steenbruggen T, van Seijen M, Wesseling J, Martín M, del Monte-Millán M, Boughey J, Goetz M, Hoskin T, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Provenzano E, Sammut S, Thomas J, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, J van ’t Veer L, Cameron D, Esserman L, Fraser Symmans W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. Npj Breast Cancer 2025, 11: 14. PMID: 39948079, PMCID: PMC11825822, DOI: 10.1038/s41523-025-00720-3.Peer-Reviewed Original ResearchResidual cancer burdenInvasive lobular carcinomaEvent-free survivalNeoadjuvant chemotherapyBreast cancerAssociated with worse event-free survivalResidual cancer burden indexInvasive lobular breast cancerCancer burdenLobular breast cancerNodal statusLobular carcinomaNAC responseT categoryPrognostic significanceStratify prognosisPatient-level dataReceptor subtypesPooled analysisMultivariate analysisPooled cohortRecursive partitioningCox modelCancer cellularityCancerRacial and ethnic disparities in conversion to mastectomy following lumpectomy
Khubchandani J, KC M, Dey P, Proussaloglou E, Valero M, Berger E, Park T, Gross C, Butler P, Fayanju O, Winer E, Golshan M, Greenup R. Racial and ethnic disparities in conversion to mastectomy following lumpectomy. Breast Cancer Research And Treatment 2025, 211: 99-110. PMID: 39937397, DOI: 10.1007/s10549-025-07625-6.Peer-Reviewed Original ResearchConceptsConversion to mastectomyNeoadjuvant chemotherapyBreast conservationStage 0-III breast cancerWhite womenBreast cancerBlack womenBreast cancer careNational Cancer DatabaseMultivariate logistic regression modelEvaluate contemporary trendsLogistic regression modelsCancer careImprove disparitiesEthnic disparitiesDiagnosis yearInitial lumpectomySocio-demographicCancer DatabaseClinical factorsMastectomyLumpectomySurgeryResultsThe studyTreatment sequenceModern-Day Hypofractionated Postmastectomy Radiation
Rybkin A, Bodofsky S, Knowlton C. Modern-Day Hypofractionated Postmastectomy Radiation. Current Breast Cancer Reports 2025, 17: 7. DOI: 10.1007/s12609-025-00570-9.Peer-Reviewed Original ResearchPostmastectomy radiationBreast cancerPost-mastectomy settingRegional nodal irradiationRadiobiological dataQuality of life metricsNodal irradiationBreast conservationEradicate tumorsComplication rateBrachial plexopathyPostmastectomy patientsToxicity profileHypofractionationFractionation schemaTherapeutic windowReviewThis reviewTissue effectsTrial dataBreastPostmastectomyStandard optionDisease controlPatientsCancerAdjuvant Atezolizumab for Early Triple-Negative Breast Cancer
Ignatiadis M, Bailey A, McArthur H, El-abed S, de Azambuja E, Metzger O, Chui S, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger G, Jassem J, Lee S, Higgins M, Zarba J, Schmidt M, Gomez H, Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch N, Bajetta E, Ohno S, Im S, Werutsky G, Gal-Yam E, Farre X, Tseng L, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron D, Viale G, Saji S, Gelber R, Piccart M. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer. JAMA 2025, 333: 1150-1160. PMID: 39883436, PMCID: PMC11783246, DOI: 10.1001/jama.2024.26886.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerAdverse eventsEarly-stage triple-negative breast cancerInvasive disease-free survival eventsTriple-negative breast cancer subtypeDisease-free survival hazard ratioInvasive disease-free survivalTreatment-related grade 3Disease-free survival eventsRandomized phase 3 trialIncidence of fatal adverse eventsRisk of recurrent diseaseIndependent data monitoring committeeAtezolizumab to chemotherapyDisease-free survivalNon-Hispanic black womenSurvival hazard ratioBreast cancer subtypesPhase 3 trialFatal adverse eventsPatient follow-upAdjuvant atezolizumabPostsurgery chemotherapyStandard chemotherapyUnraveling complexity and leveraging opportunities in uncommon breast cancer subtypes
Pareja F, Bhargava R, Borges V, Brogi E, Canas Marques R, Cardoso F, Desmedt C, Harigopal M, Lakhani S, Lee A, Leone J, Linden H, Lord C, Marchio C, Merajver S, Rakha E, Reis-Filho J, Richardson A, Sawyer E, Schedin P, Schwartz C, Tutt A, Ueno N, Vincent-Salomon A, Weigelt B, Wen Y, Schnitt S, Oesterreich S. Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes. Npj Breast Cancer 2025, 11: 6. PMID: 39856067, PMCID: PMC11760369, DOI: 10.1038/s41523-025-00719-w.Peer-Reviewed Original ResearchBreast cancerHistological subtype of breast cancerSubtypes of breast cancerBreast cancer subtypesHistological subtypesImmune microenvironmentBC presentationGenetic alterationsCancer subtypesGenetic predispositionMolecular profilingTherapeutic implicationsClinical trajectoryUnique phenotypeSubtypesBreastCancerMicroenvironmentPredispositionIndustrial air emissions and breast cancer incidence in a United States-wide prospective cohort.
Ish J, Madrigal J, Pearce J, Keil A, Fisher J, Jones R, Sandler D, White A. Industrial air emissions and breast cancer incidence in a United States-wide prospective cohort. Epidemiology 2025 PMID: 39855262, DOI: 10.1097/ede.0000000000001837.Peer-Reviewed Original ResearchBreast cancer incidenceCancer incidenceBreast cancerIncidence of breast cancerEstimate adjusted hazard ratiosHazard ratioAssociated with breast cancerIncident breast cancerConfidence intervalsBreast cancer casesAdjusted hazard ratiosCox proportional hazards regressionProportional hazards regressionParticipating residentsCancer casesHazards regressionProspective cohortStudy enrollmentElevated associationIndustrial air emissionsIndustrial carcinogensCharacterized associationsBreastFollow-upPollutant mixturesASO Visual Abstract: Association Between Delayed/Forgone Medical Care and Resource Utilization Among Women with Breast Cancer in the United States
Reddy K, Jarrell K, Berkowitz C, Hulse S, Elmore L, Fishman R, Greenup R, Mateo A, Rothman J, Sataloff D, Tchou J, Zafar S, Fayanju O. ASO Visual Abstract: Association Between Delayed/Forgone Medical Care and Resource Utilization Among Women with Breast Cancer in the United States. Annals Of Surgical Oncology 2025, 32: 2605-2606. PMID: 39847279, DOI: 10.1245/s10434-024-16776-7.Peer-Reviewed Original ResearchNeoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Loi S, Salgado R, Curigliano G, Romero Díaz R, Delaloge S, Rojas García C, Kok M, Saura C, Harbeck N, Mittendorf E, Yardley D, Suárez Zaizar A, Caminos F, Ungureanu A, Reinoso-Toledo J, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu J, Pusztai L, McArthur H. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nature Medicine 2025, 31: 433-441. PMID: 39838118, PMCID: PMC11835735, DOI: 10.1038/s41591-024-03414-8.Peer-Reviewed Original ResearchPathological complete responseIncreased pCR ratePhase 3 trialNeoadjuvant chemotherapyBreast cancerER+/HER2- BCNivolumab armPCR rateAnti-programmed death 1 agentsDouble-blind phase 3 trialEndpoint of pathologic complete responseStromal tumor-infiltrating lymphocyte levelsProgrammed death-ligand 1 expressionEstrogen receptor-positive breast cancerLower pathologic complete responseTumor-infiltrating lymphocyte levelsRandomized phase 3 trialReceptor-positive breast cancerHigh riskLigand 1 expressionEstrogen receptor-positivePrimary breast cancerTaxane-based chemotherapyDense lymphocytic infiltrateT cell immunosurveillanceClinical Implications of Breast Cancer Intrinsic Subtypes
Rios-Hoyo A, Shan N, Karn P, Pusztai L. Clinical Implications of Breast Cancer Intrinsic Subtypes. Advances In Experimental Medicine And Biology 2025, 1464: 435-448. PMID: 39821037, DOI: 10.1007/978-3-031-70875-6_21.Peer-Reviewed Original ResearchConceptsBasal-like cancersBreast cancerDistant recurrenceLuminal cancersEndocrine therapyAdjuvant chemotherapyClinical behaviorOncotype DX recurrence scorePathologic complete response rateTreated with preoperative chemotherapyExcellent long-term survivalRisk of early recurrenceBasal-like breast cancerBreast cancer intrinsic subtypesHER2-enriched cancersImmunotherapy to chemotherapyLuminal A cancersComplete response rateImmune checkpoint inhibitorsEstrogen receptor-negativeHER2-targeted therapyEstrogen receptor-positiveLevel of immune infiltrationHER2 gene amplificationAdjuvant endocrine therapyHER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers ☆
Lynce F, Martínez-Sáez O, Walbaum B, Brasó-Maristany F, Waks A, Villagrasa P, Javierre G, Sanfeliu E, Galván P, Paré L, Anderson L, Perou C, Parker J, Vivancos A, DiLullo M, Pernas S, Winer E, Overmoyer B, Mittendorf E, Bueno-Muiño C, Martín M, Prat A, Tolaney S. HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers ☆. ESMO Open 2025, 10: 104100. PMID: 39826476, PMCID: PMC11786065, DOI: 10.1016/j.esmoop.2024.104100.Peer-Reviewed Original ResearchHER2-positive inflammatory breast cancerPathological complete responseInflammatory breast cancerNeoadjuvant systemic therapyNon-IBCBreast cancerSystemic therapyEarly-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancerPredictors of pathologic complete responseHuman epidermal growth factor receptor 2 (HER2)-positive breast cancerIBC cohortIBC statusPathologic complete response rateLow axillary burdenNoninflammatory breast cancerTrastuzumab-based chemotherapyTreatment de-escalationPhase II trialClinical-pathological featuresLong-term prognosisPCR scoreAxillary burdenNeoadjuvant trastuzumabPCR rateComplete responseSocial support, fear of cancer recurrence and sleep quality in breast cancer: A moderated network analysis
Jiang Y, Wu X, Li H, Xiong Y, Knobf M, Ye Z. Social support, fear of cancer recurrence and sleep quality in breast cancer: A moderated network analysis. European Journal Of Oncology Nursing 2025, 74: 102799. PMID: 39842318, DOI: 10.1016/j.ejon.2025.102799.Peer-Reviewed Original ResearchFear of cancer recurrenceSocial supportSleep qualityPittsburgh Sleep Quality Index scalePerceived Social Support ScaleLevels of social supportEffect of social supportModerating effect of social supportHigh social supportSocial Support ScaleGeneralized anxietyBreast cancerCancer recurrenceCancer patientsSleep efficiencySupport ScaleMental healthBreast cancer patientsIndex scaleSleep problemsBuffering factorsJohnson-NeymanAnxietyFearSupportAdjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer
Filho O, Ballman K, Campbell J, Liu M, Ligibel J, Watson M, Chen E, Du L, Stover D, Carey L, Partridge A, Kirshner J, Muss H, Hudis C, Winer E, Norton L, Symmans W. Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. Journal Of Clinical Oncology 2025, 43: 1229-1239. PMID: 39746162, DOI: 10.1200/jco-24-01875.Peer-Reviewed Original ResearchConceptsDose-dense chemotherapyDisease-free survivalOverall survivalBreast cancerTumor burdenMenopausal statusLong-term disease-free survivalHormone receptor-positive breast cancerHazard ratioNode-positive breast cancerSensitivity to endocrine therapyReceptor-positive breast cancerDose-dense therapyER-negative subsetEstrogen receptor-positiveER+ breast cancerMolecular subtype classificationSustained long-term benefitsER+ cancersDose-denseER statusReceptor-positiveEndocrine therapyConventional chemotherapyChemotherapy scheduleOutcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
DeMichele A, Dueck A, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer C, Nowecki Z, Iwata H, Wolmark N, Parraga K, Rugo H, Steger G, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall K, Lu R, O’Brien P, Fesl C, Mayer E, Gnant M. Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]). Breast Cancer Research 2025, 27: 12. PMID: 39849600, PMCID: PMC11761723, DOI: 10.1186/s13058-024-01941-3.Peer-Reviewed Original ResearchConceptsLocoregional relapse-free survivalStandard adjuvant endocrine therapyYears of palbociclibAdjuvant endocrine therapyEndocrine therapyOverall survivalStage IIAPALLAS trialBreast cancerFollow-upBreast cancer-free survivalReducing breast cancer recurrenceStage IIA patientsHigher stage diseaseHormone-receptor-positiveRelapse-free survivalStage IIA diseaseYears of follow-upCancer-free survivalMedian follow-upPhase III trialsEarly breast cancerBreast cancer recurrenceBreast Cancer Study GroupNegative breast cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply